Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer.
Journal: Cancer chemotherapy and pharmacology
Published: August 26, 2025
A Phase I, Randomized, Multi-Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants.
Journal: Clinical pharmacology and therapeutics
Published: August 29, 2023
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical genitourinary cancer
Published: January 04, 2023
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Journal: Cancer chemotherapy and pharmacology
Published: September 21, 2021
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 09, 2020
Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 07, 2019
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
Journal: Journal of the National Cancer Institute
Published: September 22, 2017
Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk.
Journal: Nature communications
Published: August 08, 2016
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Journal: Pediatric blood & cancer
Published: April 10, 2015
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.
Journal: Cancer cell
Published: February 14, 2015
Last Updated: 09/26/2026